The period for CME/CE credit for this activity has expired.

Diabetes

Peak Issues (Issue 4): Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes
[Improving Clinical Outcomes: The Role of Incretin-Based Therapies]

INSTRUCTIONS

After completing the demographic questionnaire and the CME posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


CME/CE Information

PROGRAM OVERVIEW

Several landmark clinical studies have demonstrated the relationship between type 2 diabetes and an increased risk of both microvascular and macrovascular complications. Optimal glycemic control can decrease the development of microvascular disease, such as retinopathy and nephropathy, and is the central rationale for current glycemic targets in diabetic patients. Unfortunately, recent estimates indicate that only 57% of type 2 diabetes patients achieve the glycemic target of A1C < 7% recommended by the American Diabetes Association. It is now clear that both fasting and postprandial glucose control contribute to A1C, and reaching glycemic targets may require attention to both components in any given patient. There is now a spectrum of medications that can be used to treat patients with type 2 diabetes, some of which have disproportionate effects on fasting or postprandial glucose. The ability to apply specific therapies to optimize glucose control in individual patients requires familiarity with drugs that control fasting and postprandial glucose. This publication series will explore the science of postprandial plasma glucose (PPG) and its contribution to glycemic control and will highlight recent and emerging therapies that address this important target.

INTENDED AUDIENCE

This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be able to:

  • Describe the role of incretin-based therapies in the management of hyperglycemia with particular focus on PPG and improvement of clinical outcomes
  • Compare and contrast the efficacy and safety of the dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes
  • Discuss the available evidence in the published guidelines and treatment algorithms pertaining to the importance of PPG monitoring for maintaining glycemic control
  • Explain how the mechanisms of action of the incretin-based therapies address the multi-factorial complexities of type 2 diabetes

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

IMNE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURES

In compliance with the ACCME’s Standards for Commercial Support, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label or investigational use of pharmaceutical agents and medical devices.

In accordance with ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content. The following disclosures have been made:

Faculty

David D’Alessio, MD
Research Activities: Amylin Pharmaceuticals, Inc; Eli Lilly and Company; Johnson & Johnson.
Consultant: Amylin Pharmaceuticals, Inc; MannKind Corporation;
Merck & Co, Inc; Takeda Pharmaceuticals North America, Inc; Wyeth;
Sanofi-Aventis; Novo Nordisk.

Educational Partner Staff
Steve Weinman, RN
Executive Director
IMNE
Disclosures: Nothing to disclose

Sheryl Torr-Brown, PhD
Scientific Director
IMNE
Disclosures: Nothing to disclose

Robin Devine, DO
Medical Writer
IMNE
Disclosures: Nothing to disclose

Amy Groves
Director of Program Development
IMNE
Disclosures: Nothing to disclose

Betsey King
Associate Director of Program Development
IMNE
Disclosures: Nothing to disclose

CME Reviewers
Robert Hash, MD
Texas A&M Health Science Center
College of Medicine
College Station, Texas
Dr Hash has nothing to disclose

Martin Quan, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Dr Quan has nothing to disclose

DISCLAIMER

This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is partially supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

METHOD OF OBTAINING CME CREDIT

CME credit/verification is offered upon successful completion of a posttest with a minimum passing score of 70%. CME certificates will be issued to participants after receipt of the CME registration form, evaluation form, and successfully completed posttest. For those taking the test and completing the evaluation online at www.webbasedCME.com, a printable certificate will be made available upon successful completion of the posttest.

 I have read and understand the CME Information indexed above.

    •  
    • PPG-Issue-4 GraphicClick here to view the activity (.pdf)
    •  
    • Demographic Questionnaire - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • CME Posttest and Evaluation - This should be completed after the demographic questionnaire.
    •  
    •  
    • You can click on each section to preview this activity but you must be signed in to participate and receive CME credit. New to WebBasedCME.com? Click here to register.